SCG Cell Therapy

Executive Summary

SCG Cell Therapy is a Singapore-based clinical-stage biotechnology company pioneering novel T-cell receptor (TCR)-T cell immunotherapies for solid tumors. The company’s proprietary TCR screening platform enables the identification of T-cells targeting pathogen-derived antigens expressed on cancer cells, addressing the unmet need in virus-associated malignancies. Its lead candidate, SCG101, is an autologous TCR-T cell therapy designed to treat hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), a prevalent liver cancer with poor prognosis. SCG101 is currently being evaluated in a Phase 1 clinical trial, with initial data expected to demonstrate safety and early efficacy signals. The company’s approach capitalizes on the well-established link between chronic HBV infection and HCC, potentially offering a targeted therapy for this large patient population. SCG Cell Therapy operates at the intersection of oncology and infectious diseases, leveraging its platform to develop a pipeline of TCR-T therapies for other pathogen-driven cancers. The Phase 1 trial for SCG101 represents a crucial inflection point; positive interim data could validate the platform and pave the way for accelerated development. The company is privately held with a lean team of 50–200 employees, reflecting a focused R&D strategy. While early-stage, SCG Cell Therapy’s unique positioning in virus-related oncology and its robust TCR discovery platform provide a differentiated value proposition. Upcoming catalysts include clinical data readouts and potential pipeline expansion, which will be key for attracting partnerships or financing.

Upcoming Catalysts (preview)

• Q4 2026Interim Phase 1 data for SCG101 in HBV-related HCC60% success
• H1 2027Regulatory IND filing for second TCR-T program (e.g., EBV-related cancer)50% success
• H2 2026Series B financing or strategic partnership announcement70% success